Abstract: A small-sized disposable pull-on diapers having optimized waist circumferential length and leg opening length. The small-sized disposable pull-on diapers have a better performance in ease of application and waist and leg fit.

Abstract: An absorbent article facilitating sensing the presence of a body exudate in the absorbent article includes an absorbent member; a sensor coil disposed on or in the article; and an electrical double-layer capacitor disposed on or in the article and in electrical communication with the sensor coil, wherein the capacitor is in fluid communication with the absorbent member. An absorbent article system also includes a detector circuit including an exciter coil configured for electromagnetic communication with the sensor coil, and sensor electronics configured to indicate the presence of a body exudate based on changes in the electromagnetic communication between the exciter coil and the sensor coil.

Abstract: Described here are body liners and methods for treating accidental bowel leakage using one or more body liners. The body liners may be formed from one or more liner layers and in some instances may comprise one or more adhesive regions to connect the body liners to the skin of a wearer. The body liners may be configured to absorb fluid, and may selectively distribute fluid relative to the body liner.

Abstract: An individually wrapped absorbent article that is wrapped in a wrapping sheet wherein the wrapping sheet has a colored part on the inner surface on the side of the absorbent article, and the colored part of the wrapping sheet can be seen from the outside of the individually wrapped product but the absorbent article cannot be seen from the outside of the individually wrapped product.

Abstract: An electric wheelchair comprising a movable seat part (1), a body part (2) served as a support for the seat part, a seat adjustment mechanism (3) arranged under the seat part, a bottom part (4), and a crawler moving mechanism (5). The crawler moving mechanism (5) comprises two sets of crawlers arranged respectively at both sides underneath the bottom part, and each of which comprises a front crawler and a rear crawler. The bottom part (4) is comprised of a front portion and a rear portion, which are movably connected with a coupling arrangement and capable of deflection with respect to each other. The crawler moving mechanism (5) further comprises movable stretching crawlers arranged respectively at outside of the front crawler, and fixed stair-climbing crawlers arranged respectively at outside of the rear crawler, wherein a free end of the fixed stair-climbing crawler forms a specific angle relative to the rear crawler.

Abstract: The toilet-raising platform includes a platform that is configured to attach to a base of a toilet, and said platform being capable of raising and lowering the toilet as needed. The platform is constructed of a gasket that is sandwiched in between a toilet base and a plate member. The plate member includes a first waste pipe that extends downwardly, and is in fluid communication with the toilet base. The first waste pipe extends downwardly through an access plate that is positioned beneath the toilet. The access plate covers a cavity that is integrated into the floor structure beneath the toilet. The cavity includes a lifting system that works to raise and lower the first waste pipe along with the plate member and toilet.

Abstract: A flexible sheet with suspenders is used to safely handle and reposition bed-constrained patients. The suspenders include couplers and are used to secure either side of the flexible sheet to the side railing on a hospital bed. By wrapping the suspenders on one side of the flexible sheet over a patient and connecting them to the opposite side rail, a patient can be switched from a supine position to a turned position. A upper access hole and lower access gap in the flexible sheet then allow attendants to access the patients backside, where treatments can be applied. A flap is otherwise used to cover the upper access hole, being secured to the flexible sheet by a fold and a perimeter of hook-and-loop fasteners. The flexible sheet provides a safe patient handling method that will result in a decrease of workplace injuries.

Abstract: An improved incubator assembly includes a number of movable walls and a circulation system having a fluid guide apparatus adjacent each movable wall. The fluid guide apparatuses generate a first jet of air in a direction generally parallel with a wall in the closed position and a second jet of air in a direction oblique to the wall in the closed position. Whenever one of the movable walls is moved from its closed position to its open position, the jet of air that had been flowing parallel with such wall continues to flow and forms an air curtain.

Abstract: A medical cart includes a cart body, a top platform, and an elevating device. The elevating device is mounted on the cart body for supporting the top platform above the cart body and is for moving the top platform upwardly and downwardly. The elevating device includes a sleeve, a screw rod, a motor and a motor driving module. The screw rod extends through the sleeve and engages threadedly a threaded inner surface of the sleeve. The motor is connected to the screw rod and is for driving the screw rod to rotate and move with respect to the sleeve, such that the top platform is driven by the screw rod to move upwardly and downwardly with respect to the cart body.

Abstract: An examination table designed to provide a technician or practitioner easy access to various regions of a patient's body. Specifically, the examination table includes a lower support structure, an upper support structure, and an examination passageway. The upper support structure has a sliding access panel disposed on a side of the upper support structure such that the examination passageway is provided when the sliding access panel is repositioned at various measurements.

Abstract: Walking rehabilitation assistance devices that facilitate mobility in users that are rehabilitating for walking. The walking rehabilitation assistance device is essentially a support frame with wheels and a seat for the user that is attached to a flexible strap. The user straddles the seat, which in turn is attached to a tensioning device, allowing the seat to be raised so as to transfer some or all of the user's weight from the user's legs to the walking rehabilitation assistance device. In some examples, the walking rehabilitation assistance device includes a rigid seat receiver that is connected to the flexible strap, to enable the use of different styles of seats such as bicycle seats, and may provide enhanced stability in certain circumstances.

Abstract: A cuff for providing compression to a limb includes an outer wall joined to an inner wall to form a bladder, the bladder being provided with means to separate the walls to maintain a path for fluid flow into and out of the bladder characterized in that the separating means are a spacer provided on the interior of at least one wall, which separates the walls when the bladder is deflated.

Abstract: The invention includes devices and methods for reducing the appearance of cellulite in human skin. The device includes a belt having a tactile gripping portion for removably adhering to skin. When the belt is connected to a reciprocating vibratory massage device, the tactile belt grips the skin preventing substantial relative movement between the belt and the skin. On continued reciprocal movement of the belt through a stroke length and at a frequency, the outer layers of the skin are forcibly moved relative to the subcutaneous tissue layers thereby disrupting, stretching and/or tearing fat/collagen projections extending from the subcutaneous tissue into the outer skin layers thereby reducing the appearance of cellulite in the skin.

Abstract: A facial rejuvenating apparatus includes a pad having a concavity in an upper surface thereof. The concavity is configured to receive a human face. A pad breathing hole extends through the pad at a location to align with a nose of the face positioned in the concavity. A nonporous lining is provided to nest with the concavity in the pad. A lining breathing opening registers with the pad breathing opening. Stimulators, such as vibrators, are mounted in the pad to stimulate the face of a person using the apparatus.

Abstract: An implant system for imparting vibratory massage to tissue of a patient from within the body of the patient is disclosed. The system comprises an implant device configured to produce and communicate a vibration to body tissue located adjacent to the implant device. The device many include a case forming at least a portion of an exterior of the device, and a vibration generator configured to vibrate the portion of the exterior. The device may include a power supply to supply power to the vibration generator and a switch to selectively permit power from the power supply to be supplied to the vibration generator. The device may include a power receiver to receive electrical energy from a location external to the body of the patient and a signal receiver to receive signals from a location external to the body of the patient when the receiver is located in the body of the patient.

Abstract: An acupuncture needle and delivery system that facilitates the sanitary insertion and handling of the acupuncture needle in all orientations, and that does not impede the performance of the various post-insertion procedures of the sort commonly used by acupuncture practitioners. In a fully assembled pre-use state, the device includes an acupuncture needle having a filiform shaft and an enlarged head portion, an insertion tube accommodating at least the filiform shaft of the acupuncture needle to protect the filiform shaft from contamination, a stabilization sleeve slidably engaging the outer surface of the insertion tube, and retainer means for releasably securing the acupuncture needle within the insertion tube.

Abstract: A pharmaceutical product includes a container. The container, in turn, includes a receptacle having a wall including a layer of nickel or nickel alloy, the layer facing an interior of the receptacle. The product also includes a halogenated anesthetic selected from the group consisting of sevoflurane, desflurane, isoflurane, enflurane, methoxyflurane and halothane disposed within the container.

Abstract: There is provided a method for manufacturing a double-chamber container including an agent storage chamber and a solution storage chamber separated from each other by a weak seal portion, the method including the steps of: preparing a first sheet-like member including a first agent storage chamber forming portion and a first solution storage chamber forming portion whose one sides are joined to each other, as well as a second sheet-like member including a second agent storage chamber forming portion and a second solution storage chamber forming portion whose one sides are joined to each other; and forming the agent storage chamber and the solution storage chamber by joining the first and the second sheet-like members. The weak seal portion is formed by joining the one side of the first medical solution storage chamber forming portion and the one side of the second medical solution storage chamber forming portion.

Abstract: A dissolvable medication administration bag for the safe and effective crushing and administration of medication to patients who have difficulty swallowing pills. A dissolvable medication administration bag may be constructed in accordance with a pill crusher pouch embodiment into which a pill is placed prior to being crushed and subsequently the whole of pouch and the crushed pill contents are dissolved into a liquid, e.g. a beverage, as a means of reducing health hazards associated with current pill crushing practices such as inadvertent direct contact and aerosolization with subsequent inhalation of the crushed medication.

Abstract: A method for reinforcing a weak sealed portion of a multi-chamber medical container by simple processing.

Abstract: The present invention relates to a process for producing monolithic tablets. The method employs a melt-processed composition containing at least on active agent and at least one thermoplastic binder. The invention further relates to a method for cutting and deflashing a belt of pre-shaped bodies of a melt-processed composition, wherein the pre-shaped bodies are interconnected by flash.

Abstract: An apparatus for dispensing medications, including: a dispensing device storing prescription information including: identification of each medication included in a first plurality of medications; a respective dosage for each medication; and a plurality of time spans, including respective points in time, for dispensing the first plurality of medications; a cassette installed in the dispensing device and including a plurality of sealed compartments, each compartment in the plurality of sealed compartments configured to store at least one respective pill for each medication in a second plurality of medications; and at least one dispensing port. The dispensing device is configured to, within each time span in the plurality of time spans and when the second plurality of medications is in compliance with the prescription information: access each compartment via the at least one dispensing port; and extract every at least one first pill from each compartment.

Abstract: A kit for cleansing hair comprising: • a) a dry shampoo, in which the dry shampoo comprises a particulate material, preferably aluminum octenyl succinate starch or rice starch, preferably in the form of an aerosol; and • b) a substrate, preferably a flexible sheet comprising a non-woven material, preferably comprising cellulose fiber or polyester fiber and mixtures thereof, the substrate comprising a surfactant selected from the group consisting of nonionic, anionic, amphoteric and mixtures thereof.

Abstract: Described are methods for encapsulating a personal care active, comprising preparing an aqueous phase, comprising partially hydrolyzed polyvinyl alcohol and a cosmetically acceptable non-ionic surfactant, preparing an oil phase, comprising the personal care active and isocyanate or polyisocyanate, homogenizing the aqueous phase and oil phase to form an emulsion with particles less than one micron, and forming a dispersion of polyurea core-shell particles containing the personal care active by contacting the emulsion with an aqueous amine solution.

Abstract: A method for improving the appearance of skin depth, dimensionality or undertones by topically applying a composition containing composite particulates made by (a) solvating a clear or translucent thermoplastic material with solvent in an amount sufficient to swell the material; (b) combining the solvated mixture of (a) with one or more colorants; (c) removing the solvent to form a composite particulate, (d) formulating the composite particulate into a topical cosmetic composition for application to skin.

Abstract: The present invention relates to bleaching composition for keratin fibers, especially human hair, comprising at least one compound with bleaching and/or highlighting effect and a calcium salt. Further object of the present invention is the use of at least one calcium salt in a bleaching and/or highlighting composition for keratin fibers, especially for human hair, comprising at least one compound with bleaching and/or highlighting effect for preventing temperature increase going above 40° C., preferably above 45° C. and more preferably above 50° C. in a period of at least 60 min after mixing water free bleaching and/or highlighting composition and oxidizing lotion.

Abstract: Provided is a novel drug capable of inhibiting excessive formation of melanin in skin and a skin whitening agent incorporated therewith. Phenylethyl cinnamate is incorporated as an active ingredient.

Abstract: An emulsified cosmetic composition comprising the following ingredients (A), (B), (C), and (D): (A) 0.1% by weight or more and 15% by weight or less of at least one compound selected from the group consisting of a sphingosine or a salt thereof, a pseudo-sphingosine or a salt thereof, and an ionic surfactant, (B) at least one compound selected from the group consisting of a monoglyceryl di-fatty acid ester and a sorbitan di-fatty acid ester, (C) at least one compound selected from the group consisting of a ceramide, an alcohol having 12 to 22 carbon atoms, a monoglyceryl mono-C12 to C22 fatty acid ester, a mono-C12 to C22 alkyl glyceryl ether, and a sorbitan mono-C12 to C22 fatty acid ester, and (D) water, wherein in the ingredients (A), (B), and (C), (1) a weight ratio of (A)/((B)+(C)) is 0.04 or more and 1 or less, (2) a mole fraction of (B)/((B)+(C)) is 0.02 or more and 0.45 or less, and (3) a maximum mole fraction of one compound as a single component in the ingredient (B) and the ingredient (C) is 0.

Abstract: The invention relates to a physiologically acceptable composition, especially a cosmetic composition, comprising at least one polar modified polymer, as well as to methods of using such compositions.

Abstract: Disclosed are cosmetic toner formulations and methods for their use comprising botanical plant extracts and a cosmetic vehicle.

Abstract: An eye drop composition comprising a carboxyvinyl polymer and a monoterpene, and having a viscosity from 200 to 100,000 mPa·s. The monoterpene may be at least one selected from the group consisting of menthol, camphor and borneol. The carboxyvinyl polymer content may be from 0.001 to 10 w/v % with respect to the total volume of the eye drop composition, and the monoterpene content may be from 0.0001 to 1 w/v % with respect to the total volume of the eye drop composition.

Abstract: The purpose of the invention is to provide a press-coated orally-disintegrating tablet having a powder/granular material with poor formability in its inner core, which has an excellent disintegrability and a suitable hardness as a whole tablet. Furthermore, the invention is a press-coated orally-disintegrating tablet with an outer layer surrounding an inner core wherein the inner core has a thickness in the range of 30 to 80% per that of the whole tablet, and the outer layer comprises (a) microcrystalline cellulose, (b) a sugar or a sugar alcohol, and (c) one or more particular ingredients selected from the group consisting of crospovidone, starches, low-substituted hydroxypropylcellulose and carmellose.

Abstract: A method for treating a periodontal disease affecting a periodontal pocket of a patient. The method comprises inserting an oral delivery device into the periodontal pocket at a frequency of about once every 4 days to about once every 6 weeks. The oral delivery device is a controlled release solid unit dosage form suitable for insertion into a periodontal pocket of a patient, comprising a therapeutically effective amount of at least one anti-inflammatory agent, at least one antibacterial agent, or the combination of at least one anti-inflammatory agent and at least one antibacterial agent.

Abstract: A delivery system for water-insoluble pharmaceutical active ingredients is provided. The delivery system includes water-insoluble pharmaceutical active ingredient(s), organic solvent(s) and amphiphilic co-solvent(s), and a mixture of hydrophilic and hydrophobic non-ionic surfactants. Upon dilution in an aqueous medium, this formulation forms spontaneously dispersion of non-ionic surfactant nanoparticles.

Abstract: A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an oil-in-water emulsion which contains one or more hydrofluoroalkane (HFA) propellants and one or more keratolytic agents. The keratolytic agent may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. The foam is stable on the skin for at least 5 minutes at body temperature and disappears into the skin upon rubbing or after prolonged standing. The formulations may not contain additional co-solvents or non-HFA co-propellants. The formulations demonstrate reduced intensity of the odor and/or color associated with the keratolytic agent(s) as compared to conventional formulations containing keratolytic agents.

Abstract: A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid molecules and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated molecules display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or negatively-charged drugs with other anti-neoplastic drugs (the positively-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value.

Abstract: Vesicle compositions are provided that comprise a therapeutic compound. The vesicle compositions may be capable of releasing the therapeutic compound in response to the presence of an external trigger. The vesicle compositions may comprise a plurality of biocompatible vesicles. The biocompatible vesicles may comprise a therapeutic compound for treatment of a patient in need thereof, and one or more cross-linkages between two or more of the biocompatible vesicles, each cross-linkage comprising a chemical sensing moiety and a sensed moiety. In some embodiments, the therapeutic compound may be any compound that provides palliative, curative, or otherwise beneficial effects to a patent.

Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.

Abstract: A composition comprises a water-soluble polymer matrix in which are dispersed droplets of oil, the composition comprising an active principle. The invention includes embodiments in which the active principle is included in at least some of the oil droplets as well as embodiments in which the oil droplets are free of active principle. The oil droplets are released as the matrix containing them dissolves in an aqueous medium. In one embodiment, the oil droplets are substantially immobilized in or by the matrix and the immobilizing feature is lost as the matrix dissolves in aqueous media. In certain embodiments, the oil drops may collectively be referred to as the oil phase of the composition of the invention. The product may be in the form of mini-beads. The oil phase and/or the polymer matrix may each include a surfactant.

Abstract: An organic compound nano-powder comprising a granular organic compound with an average particle diameter of 500 nm or less and a 90%-diameter of less than 1500 nm and a carbohydrate compound comprising at least any one of a sugar and a sugar alcohol and with amount of 0.3 times or more by mass relative to amount of the organic compound, a method for producing the same, and a suspension having the organic compound dispersed in a liquid dispersion medium in which the organic compound is insoluble or poorly soluble.

Abstract: The present invention relates to a hormonal contraceptive including 21 to 25 hormone-containing daily units, which contain a combination of ethinyloestradiol in an amount of ?25 ?g and chlormadinone acetate in an amount of ?5 mg, and optionally 7 to 3 hormone-free daily units for oral administration to women.

Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.

Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.

Abstract: A composition of matter for use in encapsulating a drug is expressed by formula (1) or formula (2): wherein R1 and R2 are each independently a hydrogen atom or a substituted or unsubstituted, linear or branched alkyl group having 1 to 12 carbon atoms; A is a hydrophilic polymer chain; L1 and L3 are each a linking group; B is a cation-containing group; R3 is a side chain of an amino acid; z is an integer of 5 to 500; x is an integer of 40% or more of z; y is 0 or a positive integer; z-x-y is 0 or a positive integer; p is an integer of 1 to 10; and q is an integer of 1 to 10.

Abstract: A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.

Abstract: The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa.

Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.

Abstract: An ocular composition consisting essentially of purified water, PEG-80 sorbitan laurate, sodium trideceth sulfate, PEG-150 distearate, sodium lauroamphoacetate, cocamidopropyl hydroxysultaine, sodium laureth-13 carboxylate, sodium chloride, PEG-15 cocopolyamine, polyhexamethylene biguanide, potassium sorbate, 1,2 hexanediol, and caprylyl glycol. The composition can be applied to a fabric pad for use as an eyelid cleanser, where the fabric pad is pre-moistened with the composition and packaged for use. The composition may also be used in an eyelid treatment kit for convenient combination treatments to improve overall eyelid hygiene and adjunctive eyelid therapy.

Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.

Abstract: The present invention relates to the discovery that compounds isolated from the leaves of the plant Eucalyptus camaldulensis can be used to treat or prevent hyperglycemia and/or hypertension.